Search
Nelarabine
go.drugbank.com/drugs/DB01280ApprovedInvestigational[L40878] T-cell acute lymphoblastic leukemia and lymphoma are relatively rare T-cells malignancy, with only 20 to 25% of patients diagnosed with acute lymphoblastic leukemia and 1.7% of patients diagnosed … Nelarabine is an antineoplastic agent that is typically used to treat acute T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL
Synonyms: 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purineProducts: NELARAMAX 250 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ , 6 ADET, NELARAMAX 250 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ , 1 ADETDiosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalDiosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040] … Chronic venous insufficiency is a common condition the western population.
Synonyms: 3',5,7-trihydroxy-4'-methoxyflavone-7-rutinoside, 3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucosideMixtures: DIOKERN 450 MG/50 MG FILM KAPLI TABLET,30 ADET, VARIDOS 450 MG/50 MG FILM KAPLI TABLET, 30 ADETMagaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
International brands: Almagel T, Almadrat TMixtures: M A L D I M, ASIDOPAN PLUS 200 ML SUSPANSIYONAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261276] It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. … gamma 1 (IgG1).
Products: ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML, EYLEA 40 MG/ML INTRAVITREAL ENJEKSIYON ICIN COZELTI ICEREN FLAKON, 1 ADETAluminum acetate
go.drugbank.com/drugs/DB14518ApprovedInvestigationalMixtures: ZISUAL-C, SPERTI PREPARATION HProducts: ACETATO DE ALUMINIO 15 MG/100 ML SOLUCION TOPICA, ACETATO DE ALUMINIO 0.118G/100 MLPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MGFoscarnet
go.drugbank.com/drugs/DB00529ApprovedInvestigationalAn antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Products: FOSCAVIR INFUSION 24 mg/ml, Foscarnet Tillomed 24 mg/ml InfusionslösungRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG).
Products: Rystiggo 280 mg/2 ml Enjeksiyonluk Çözelti, 1 adetInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalInclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density … lipoprotein cholesterol (LDL-C) levels.
Categories: Compounds used in a research, industrial, or household setting, Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsProducts: LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML